{"id":"supportive-care-ripertamab","safety":{"commonSideEffects":[{"rate":"null","effect":"Hypertension"},{"rate":"null","effect":"Fatigue"},{"rate":"null","effect":"Nausea"}]},"_chembl":null,"_dailymed":null,"mechanism":{"_ai_source":"groq-llama-8b","explanation":"Ripretinib works by selectively binding to the ATP-binding pocket of the KIT and PDGFRA kinases, thereby inhibiting their activity and preventing the activation of downstream signaling pathways that promote cancer cell growth and survival. This leads to a reduction in tumor size and a delay in disease progression.","oneSentence":"Ripretinib targets and inhibits the activity of KIT and PDGFRA kinases, which are involved in the growth and spread of cancer cells.","_ai_confidence":"high"},"_scrapedAt":"2026-03-28T01:36:59.218Z","_scrapedBy":"cloudflare-swarm","_wikipedia":null,"indications":{"approved":[{"name":"Advanced gastrointestinal stromal tumor (GIST) with a KIT or PDGFRA mutation"},{"name":"Advanced or metastatic melanoma with a KIT or PDGFRA mutation"}]},"trialDetails":[{"nctId":"NCT06405100","phase":"PHASE3","title":"Efficacy and Safety of Tacrolimus in Combination With Ripertamab in the Initial Treatment of Patients With MCD","status":"NOT_YET_RECRUITING","sponsor":"Air Force Military Medical University, China","startDate":"2024-05","conditions":"Minimal Change Disease","enrollment":81}],"_emaApprovals":[],"_faersSignals":[],"_approvalHistory":[],"publicationCount":0,"rwe":[],"genericFilers":[],"relatedDrugs":[],"labelChanges":[],"biosimilarFilings":[],"pricing":[],"formularyStatus":[],"manufacturing":[],"companionDiagnostics":[],"competitors":[],"timeline":[],"patents":[],"ownershipHistory":[],"trials":[],"biosimilars":[],"latestUpdates":[],"references":[],"tags":[],"ecosystem":[],"genericManufacturerList":[],"offLabel":[],"developmentCodes":[],"aliases":["Test group 2"],"phase":"phase_3","status":"active","brandName":"Supportive care+Ripertamab","genericName":"Supportive care+Ripertamab","companyName":"Air Force Military Medical University, China","companyId":"air-force-military-medical-university-china","modality":"Small molecule","firstApprovalDate":"","aiSummary":"Ripertamab is an antibody used in supportive care for Minimal Change Disease, as seen in clinical trials. It is typically combined with other treatments such as prednisone or tacrolimus, and its mechanism of action is as an antibody.","enrichmentLevel":3,"visitCount":0,"trialStats":{"total":0,"withResults":0},"verificationStatus":"verified","dataCompleteness":{"mechanism":true,"indications":true,"safety":true,"trials":true,"score":4}}